The FBR analyst mentioned the preclinical 3422 data at AASLD but that's a rehash of old stuff IMO and a non-event. They are not presenting the 3422 monotherapy data from the 3422 trial at AASLD ... I am not aware of any analysts having hyped that ... the release of 3422 trial data will be a pivotal event ... that trial is in the good hands of Prof Gane and it will be run well!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.